ASCO: Endocrine Tx Noninferior for HR+, HER2− Breast Cancer
MONDAY, June 4, 2018 -- For women with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer with a midrange 21-gene recurrence score, adjuvant endocrine therapy is noninferior to chemoendocrine therapy, according to a study published online June 3 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.
Joseph A. Sparano, M.D., from the Montefiore Medical Center in Bronx, N.Y., and colleagues randomized 69 percent of 9,719 eligible women with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer with a midrange recurrence score of 11 to 25 to either chemoendocrine therapy or endocrine therapy alone.
The researchers found that in the analysis of invasive disease-free survival, endocrine therapy was noninferior to chemoendocrine therapy (hazard ratio for invasive disease recurrence, second primary cancer, or death, 1.08; 95 percent confidence interval, 0.94 to 1.24; P = 0.26). Similar rates of invasive disease-free survival (83.3 and 84.3 in the endocrine-therapy group and chemoendocrine therapy group, respectively), freedom from disease recurrence at a distant site (94.5 and 95.0 percent), or at a distant or local-regional site (92.2 and 92.9 percent), and overall survival (93.9 and 93.8 percent) were seen in the two treatment groups at nine years.
"Adjuvant endocrine therapy and chemoendocrine therapy had similar efficacy in women with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer who had a midrange 21-gene recurrence score," the authors write.
Several authors disclosed financial ties to Genomic Health, which partially funded the study; one author holds a patent issued and licensed to Genomic Health.
© 2019 HealthDay. All rights reserved.
Posted: June 2018